Ipsen strikes €1bn deal to acquire French biotech ImCheck Therapeutics
The move will boost its oncology pipeline, adding a potential first-in-class anti-BTN3A monoclonal antibody for acute myeloid leukaemia.
List view / Grid view
The move will boost its oncology pipeline, adding a potential first-in-class anti-BTN3A monoclonal antibody for acute myeloid leukaemia.
Strengthens its downstream process offering with the addition of JSR’s Amsphere Protein A resin technology.
20 October 2025 | By
The balance between speed, scale, and compliance has never been more critical. As GLP-1s, biosimilars, and advanced therapies reshape global priorities, pharma leaders face a new question: how can manufacturing infrastructure evolve fast enough to keep pace?
He joins the US company with over two decades of experience in pharma operations, supply chain and manufacturing.
The study is one of three to start, along with those in hidradenitis suppurativa and radiographic axial spondyloarthritis.
7 October 2025 | By Rapid Micro Biosystems
This webinar showcases a rapid microbial method that can help to address the time to result challenge posed by short shelf-life radiopharmaceuticals.
Contract development and manufacturing services will be provided as Rezon Bio from Poland, with the biosimilars company operating from Switzerland.
The US FDA approvals make the drug the first IL-23 inhibitor to be licensed for two common skin conditions.
The deal will support the biotech in its plans to advance bispecific antibody petosemtamab in multiple oncology indications.
The anti-amyloid monoclonal antibody is part of the class of medicines representing the first disease-modifying therapies for the neurodegenerative disease.
EPR Issue 3 includes articles on microbiology, downstream processing, manufacturing, drug formulation and more.
The new $5 billion manufacturing site is set to become the company’s first integrated facility for API and drug product manufacturing.
Prague-based pharma company is acquired by GTCR from Advent.
Gains access to potential breakthrough atherosclerotic cardiovascular disease biologic therapy pacibekitug.
As an important policy tool, the new editions by the WHO mark a “significant” step in broadening access to new medicines with proven clinical benefits.